Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | YAP1 | P46937 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388401 | 1.00 | PDE4B (0.54) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL13315211 | 1.00 | PDE4B (0.54) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL3388396 | 1.00 | PDE4B (0.54) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL19918950 | 1.00 | PDE4B (0.54) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL376172 | 0.92 | PDE4B (0.56) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL28542087 | 0.92 | PDE4B (0.56) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL30661643 | 0.92 | HSD11B1 (0.48) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL2852833 | 0.92 | HSD11B1 (0.48) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL20121078 | 0.92 | PDE4B (0.56) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL2852829 | 0.92 | HSD11B1 (0.48) | PDE4BSMN1; SMN2NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367800-B9 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | IPHARMA H K LTD (HK) | 2021-10-20 | — | — | EP | disclosed |
| EP-2367800-B1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INT (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-9676762-B2 | Pyrimidine compounds containing seven-membered fused ring systems | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676762-B2 | Pyrimidine compounds containing seven-membered fused ring systems | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20160362404-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| US-20160362404-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| US-20150376141-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-31 | — | — | US | disclosed |
| US-20150376141-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-31 | — | — | US | disclosed |
| US-20150376141-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-31 | — | — | US | disclosed |
| US-20140371205-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
| US-8846689-B2 | Substituted pyrimidines for the treatment of diseases such as cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846689-B2 | Substituted pyrimidines for the treatment of diseases such as cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20110288071-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| US-20110288071-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| US-20110288071-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| EP-2367800-A2 | NEW COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010058032-A2 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010026122-A1 | HETEROCYCLIC PIM-KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026121-A1 | BICYCLIC KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009109576-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371205-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | TYMP, HPRT1, TYMS | PDE4B 2672/4885SMN1; SMN2 504/4885NPC1 1446/4885 |
| US-20160362404-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | PDE4B 2272/4885SMN1; SMN2 612/4885NPC1 84/4885 |
| US-20150376141-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | PDE4B 2551/4885SMN1; SMN2 381/4885NPC1 62/4885 |
| US-20110288071-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | TYMP, HPRT1, TYMS | PDE4B 2672/4885SMN1; SMN2 504/4885NPC1 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.